Abstract
Hypoxia (oxygen levels below 1–2%) is a common finding in solid tumors. The development of tumor hypoxia can be viewed as an imbalance between oxygen supply and demand. Tumor hypoxia significantly impacts tumor radiosensitivity and subsequently leads to poor clinical outcomes in patients treated with radiation therapy. The presence of molecular oxygen supports the production of lethal DNA damage in irradiated cells; therefore, the radiation dose required under severely hypoxic conditions to achieve a certain biological effect is generally 2- to 3-fold higher than the dose needed under normoxic conditions (i.e., oxygen enhancement ratio (OER) = 2–3). Several therapeutic approaches have been historically used and are emerging to target tumor hypoxia in order to improve radiation therapy outcomes. These include hyperbaric oxygen, correction of anemia, combination of radiation with carbogen and nicotinamide (ARCON), oxygen mimetics such as nimorazole, hypoxia-activated prodrugs, vascular normalization strategies (reviewed in Chap. 12), and emerging therapies to target tumor oxidative phosphorylation. Even though tumor hypoxia has long been established as a negative factor for radiation therapy outcomes in the clinic, we still lack robust, widely available, and adequately validated biomarkers for assessing tumor hypoxia in patients. This has not only significantly impeded the investigation of the efficacy of hypoxia modifiers, but it has also resulted in an inability to accurately select patients who are likely to benefit from such treatment. It is likely that only when hypoxia biomarkers are widely available will hypoxia modification enter the era of personalized medicine and improve outcomes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Algire C, Moiseeva O, Deschênes-Simard X, Amrein L, Petruccelli L, Birman E, Viollet B, Ferbeyre G, Pollak MN (2012) Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila) 5(4):536–543. https://doi.org/10.1158/1940-6207.CAPR-11-0536
Alper T, Howard-Flanders P (1956) Role of oxygen in modifying the radiosensitivity of E. coli B. Nature 178(4540):978–979
Ames BN, Shigenaga MK, Hagen TM (1993) Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 90(17):7915–7922
Anon. (n.d.-a) MEPRON (atovaquone) Suspension-GSKSource
Anon. (n.d.-b) Wellvone 750mg/5ml oral suspension - Summary of Product Characteristics (SmPC)—(emc)
Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Huether M, Kelly CJ, Pirovano G, Buffa FM, Hammond EM, Stratford M, Muschel RJ, Higgins GS, McKenna WG (2016) The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. Nat Commun 7. https://doi.org/10.1038/ncomms12308
Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS (2018) Oxidative phosphorylation as an emerging target in cancer therapy. Clin Cancer Res 24(11):2482–2490. https://doi.org/10.1158/1078-0432.CCR-17-3070
Asquith JC, Watts ME, Patel K, Smithen CE, Adams GE (1974) Electron affinic sensitization. V. Radiosensitization of hypoxic bacteria and mammalian cells in vitro by some nitroimidazoles and nitropyrazoles. Radiat Res 60(1):108–118
Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30(6):586–623. https://doi.org/10.1210/er.2008-0047
Benej M, Hong X, Vibhute S, Scott S, Wu J, Graves E, Le Q-T, Koong AC, Giaccia AJ, Yu B, Chen C-S, Papandreou I, Denko NC (2018) Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A 115(42):10756–10761. https://doi.org/10.1073/pnas.1808945115
Bennett M, Feldmeier J, Smee R, Milross C (2005) Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev 4:CD005007. https://doi.org/10.1002/14651858.CD005007.pub2
Bennewith KL, Durand RE (2004) Quantifying transient hypoxia in human tumor xenografts by flow cytometry. Cancer Res 64(17):6183–6189. https://doi.org/10.1158/0008-5472.CAN-04-0289
Bentzen J, Toustrup K, Eriksen JG, Primdahl H, Andersen LJ, Overgaard J (2015) Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study. Acta Oncol 54(7):1001–1007. https://doi.org/10.3109/0284186X.2014.992547
Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J (2003) HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J 22(16):4082–4090. https://doi.org/10.1093/emboj/cdg392
Birsoy K, Possemato R, Lorbeer FK, Bayraktar EC, Thiru P, Yucel B, Wang T, Chen WW, Clish CB, Sabatini DM (2014) Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature 508(7494):108–112. https://doi.org/10.1038/nature13110
Birth D, Kao W-C, Hunte C (2014) Structural analysis of atovaquone-inhibited cytochrome bc1 complex reveals the molecular basis of antimalarial drug action. Nat Commun 5:4029. https://doi.org/10.1038/ncomms5029
Bleehen NM, Wiltshire CR, Plowman PN, Watson JV, Gleave JR, Holmes AE, Lewin WS, Treip CS, Hawkins TD (1981) A randomized study of misonidazole and radiotherapy for grade 3 and 4 cerebral astrocytoma. Br J Cancer 43(4):436–442
Brown JM (1979) Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 52(620):650–656. https://doi.org/10.1259/0007-1285-52-620-650
Buffa FM, Harris AL, West CM, Miller CJ (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 102(2):428–435. https://doi.org/10.1038/sj.bjc.6605450
Cao X, Wu Y, Wang J, Liu K, Wang X (2017) The effect of metformin on mortality among diabetic cancer patients: a systematic review and meta-analysis. JNCI Cancer Spectr 1(1). https://doi.org/10.1093/jncics/pkx007
Carreau A, Hafny-Rahbi BE, Matejuk A, Grillon C, Kieda C (2011) Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 15(6):1239–1253. https://doi.org/10.1111/j.1582-4934.2011.01258.x
Cavalli LR, Varella-Garcia M, Liang BC (1997) Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ 8(11):1189–1198
Cerniglia GJ, Pore N, Tsai JH, Schultz S, Mick R, Choe R, Xing X, Durduran T, Yodh AG, Evans SM, Koch CJ, Hahn SM, Quon H, Sehgal CM, Lee WMF, Maity A (2009) Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy. PLoS One 4(8):e6539. https://doi.org/10.1371/journal.pone.0006539
Chakraborty C, Das S (2016) Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers. Tumour Biol 37(5):5705–5714. https://doi.org/10.1007/s13277-016-4907-3
Chapman JD (1979) Hypoxic sensitizers--implications for radiation therapy. N Engl J Med 301(26):1429–1432. https://doi.org/10.1056/NEJM197912273012606
Chen D, Sun X, Zhang X, Cao J (2018) Targeting mitochondria by anthelmintic drug atovaquone sensitizes renal cell carcinoma to chemotherapy and immunotherapy. J Biochem Mol Toxicol 32(9):e22195. https://doi.org/10.1002/jbt.22195
Cheung TW (1999) Overdose of atovaquone in a patient with AIDS. AIDS 13(14):1984–1985
Choudhry H, Harris AL (2018) Advances in hypoxia-inducible factor biology. Cell Metab 27(2):281–298. https://doi.org/10.1016/j.cmet.2017.10.005
Dang CV, Lewis BC, Dolde C, Dang G, Shim H (1997) Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 29(4):345–354
Dang CV, Semenza GL (1999) Oncogenic alterations of metabolism. Trends Biochem Sci 24(2):68–72. https://doi.org/10.1016/S0968-0004(98)01344-9
Dang K, Myers KA (2015) The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci 16(3):6353–6372. https://doi.org/10.3390/ijms16036353
Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM (2006) The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1alpha. Cancer Res 66(7):3688–3698. https://doi.org/10.1158/0008-5472.CAN-05-4564
De Bruycker S, Vangestel C, Van den Wyngaert T, Pauwels P, Wyffels L, Staelens S, Stroobants S (2019) 18F-Flortanidazole hypoxia PET holds promise as a prognostic and predictive imaging biomarker in a lung cancer xenograft model treated with metformin and radiotherapy. J Nucl Med 60(1):34–40. https://doi.org/10.2967/jnumed.118.212225
DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7(1):11–20. https://doi.org/10.1016/j.cmet.2007.10.002
Dengler VL, Galbraith M, Espinosa JM (2014) Transcriptional regulation by hypoxia inducible factors. Crit Rev Biochem Mol Biol 49(1):1–15. https://doi.org/10.3109/10409238.2013.838205
Dewhirst MW (2009) Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 172(6):653–665. https://doi.org/10.1667/RR1926.1
Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8(6):425–437. https://doi.org/10.1038/nrc2397
Dische S (1985) Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother Oncol 3(2):97–115
Dische S, Saunders M, Barrett A, Harvey A, Gibson D, Parmar M (1997) A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 44(2):123–136
DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee Y-C, Cohn DE, Spirtos NM, Tewari KS, Muller C, Gajewski WH, Steinhoff MM, Monk BJ (2014) Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol 32(5):458–464. https://doi.org/10.1200/JCO.2013.51.4265
Doktorova H, Hrabeta J, Khalil MA, Eckschlager T (2015) Hypoxia-induced chemoresistance in cancer cells: the role of not only HIF-1. Biomed Papers 159(2):166–177. https://doi.org/10.5507/bp.2015.025
Dowling RJO, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67(22):10804–10812. https://doi.org/10.1158/0008-5472.CAN-07-2310
Dubois L, Landuyt W, Haustermans K, Dupont P, Bormans G, Vermaelen P, Flamen P, Verbeken E, Mortelmans L (2004) Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 91(11):1947–1954. https://doi.org/10.1038/sj.bjc.6602219
Dunst J, Stadler P, Becker A, Kuhnt T, Lautenschläger C, Molls M, Haensgen G (2001) Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 177(9):469–473
Dunwoodie SL (2009) The role of hypoxia in development of the mammalian embryo. Dev Cell 17(6):755–773. https://doi.org/10.1016/j.devcel.2009.11.008
Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM (1999) Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237:97–132
Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, Thompson CB (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64(11):3892–3899. https://doi.org/10.1158/0008-5472.CAN-03-2904
Eschmann S-M, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, Machulla H-J, Bares R (2005) Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 46(2):253–260
Falk SJ, Ward R, Bleehen NM (1992) The influence of carbogen breathing on tumour tissue oxygenation in man evaluated by computerised p02 histography. Br J Cancer 66(5):919–924
Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-Demonacos M, Cappello AR, Martinez-Outschoorn UE, Sotgia F, Lisanti MP (2016) Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells. Oncotarget 7(23):34084–34099. https://doi.org/10.18632/oncotarget.9122
Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris AL, Domarkas J, Lord S, Baldry C, Gilbert FJ (2015) Imaging tumour hypoxia with positron emission tomography. Br J Cancer 112(2):238–250. https://doi.org/10.1038/bjc.2014.610
Fokas E, Im JH, Hill S, Yameen S, Stratford M, Beech J, Hackl W, Maira S-M, Bernhard EJ, McKenna WG, Muschel RJ (2012) Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature. Cancer Res 72(1):239–248. https://doi.org/10.1158/0008-5472.CAN-11-2263
Fry M, Pudney M (1992) Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 43(7):1545–1553
Fukuda R, Zhang H, Kim J-w, Shimoda L, Dang CV, Semenza GL (2007) HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129(1):111–122. https://doi.org/10.1016/j.cell.2007.01.047
Gao X, Liu X, Shan W, Liu Q, Wang C, Zheng J, Yao H, Tang R, Zheng J (2018) Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma. Am J Cancer Res 8(9):1697–1711
Gatenby RA, Kessler HB, Rosenblum JS, Coia LR, Moldofsky PJ, Hartz WH, Broder GJ (1988) Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 14(5):831–838. https://doi.org/10.1016/0360-3016(88)90002-8
Gaude E, Frezza C (2016) Tissue-specific and convergent metabolic transformation of cancer correlates with metastatic potential and patient survival. Nat Commun 7:13041. https://doi.org/10.1038/ncomms13041
Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL (2001) Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 61(21):7992–7998
Gillies RM, Robinson SP, McPhail LD, Carter ND, Murray JF (2011) Immunohistochemical assessment of intrinsic and extrinsic markers of hypoxia in reproductive tissue: differential expression of HIF1α and HIF2α in rat oviduct and endometrium. J Mol Hist 42(4):341–354. https://doi.org/10.1007/s10735-011-9338-2
Ginouvès A, Ilc K, Macías N, Pouysségur J, Berra E (2008) PHDs overactivation during chronic hypoxia "desensitizes" HIFalpha and protects cells from necrosis. Proc Natl Acad Sci U S A 105(12):4745–4750. https://doi.org/10.1073/pnas.0705680105
Goldmann E (1908) The growth of malignant disease in man and the lower animals, with special reference to the vascular system. Proc R Soc Med 1(Surg Sect):1–13
Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26(312):638–648. https://doi.org/10.1259/0007-1285-26-312-638
Grimes DR, Kelly C, Bloch K, Partridge M (2014) A method for estimating the oxygen consumption rate in multicellular tumour spheroids. J R Soc Interface 11(92):20131124. https://doi.org/10.1098/rsif.2013.1124
Grkovski M, Schwartz J, Rimner A, Schöder H, Carlin SD, Zanzonico PB, Humm JL, Nehmeh SA (2016) Reproducibility of 18F-fluoromisonidazole intratumour distribution in non-small cell lung cancer. EJNMMI Res 6. https://doi.org/10.1186/s13550-016-0210-y
Hall E, Giaccia A (2011) Radiobiology for the radiologist, 7th edn. Lippincottt Williams & Wilkins, Philadelphia, PA
Hammond EM, Asselin MC, Forster D, O'Connor JP, Senra JM, Williams KJ (2014) The meaning, measurement and modification of hypoxia in the laboratory and the clinic. Clin Oncol (R Coll Radiol) 26(5):277–288. https://doi.org/10.1016/j.clon.2014.02.002
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
Harris BHL, Barberis A, West CML, Buffa FM (2015) Gene expression signatures as biomarkers of tumour hypoxia. Clin Oncol (R Coll Radiol) 27(10):547–560. https://doi.org/10.1016/j.clon.2015.07.004
Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D (2002) Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7(6):492–508
Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156(4):1363–1380
Heiden MGV, DeBerardinis RJ (2017) Understanding the intersections between metabolism and cancer biology. Cell 168(4):657–669. https://doi.org/10.1016/j.cell.2016.12.039
Held KD, Harrop HA, Michael BD (1984) Effects of oxygen and sulphydryl-containing compounds on irradiated transforming DNA. II. Glutathione, cysteine and cysteamine. Int J Radiat Biol Relat Stud Phys Chem Med 45(6):615–626
Henke M, Laszig R, Rübe C, Schäfer U, Haase K-D, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362(9392):1255–1260. https://doi.org/10.1016/S0140-6736(03)14567-9
Henke M, Mattern D, Pepe M, Bézay C, Weissenberger C, Werner M, Pajonk F (2006) Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 24(29):4708–4713. https://doi.org/10.1200/JCO.2006.06.2737
Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J (2012) Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9(12):674–687. https://doi.org/10.1038/nrclinonc.2012.171
Hoskin P, Rojas A, Saunders M (2009) Accelerated radiotherapy, carbogen, and nicotinamide (ARCON) in the treatment of advanced bladder cancer: mature results of a phase II nonrandomized study. Int J Radiat Oncol Biol Phys 73(5):1425–1431. https://doi.org/10.1016/j.ijrobp.2008.06.1950
Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI (2010) Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol. https://doi.org/10.1200/JCO.2010.28.4950
Hudson AT, Dickins M, Ginger CD, Gutteridge WE, Holdich T, Hutchinson DB, Pudney M, Randall AW, Latter VS (1991) 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp Clin Res 17(9):427–435
Hughes VS, Wiggins JM, Siemann DW (2018) Tumor oxygenation and cancer therapy—then and now. Br J Radiol 92(1093):20170955. https://doi.org/10.1259/bjr.20170955
Hunter RW, Hughey CC, Lantier L, Sundelin EI, Peggie M, Zeqiraj E, Sicheri F, Jessen N, Wasserman DH, Sakamoto K (2018) Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat Med 24(9):1395. https://doi.org/10.1038/s41591-018-0159-7
Hutchinson F (1961) Sulfhydryl groups and the oxygen effect on irradiated dilute solutions of enzymes and nucleic acids. Radiat Res 14:721–731
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292(5516):468–472. https://doi.org/10.1126/science.1059796
Jain RK (2014) Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 26(5):605–622. https://doi.org/10.1016/j.ccell.2014.10.006
Janssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Marres HA, de Bree R, van der Kogel AJ, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH (2012) Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol 30(15):1777–1783. https://doi.org/10.1200/JCO.2011.35.9315
Jiang M, Li X, Quan X, Li X, Zhou B (2018, 2018) Clinically correlated MicroRNAs in the diagnosis of non-small cell lung cancer: a systematic review and meta-analysis. Biomed Res Int. https://doi.org/10.1155/2018/5930951
Jones RG, Thompson CB (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23(5):537–548. https://doi.org/10.1101/gad.1756509
Kaanders JHAM, Pop LAM, Marres HAM, Bruaset I, van den Hoogen FJA, Merkx MAW, van der Kogel AJ (2002) ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 52(3):769–778
Kaluz S, Kaluzová M, Liao S-Y, Lerman M, Stanbridge EJ (2009) Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795(2):162–172. https://doi.org/10.1016/j.bbcan.2009.01.001
Kedderis GL, Miwa GT (1988) The metabolic activation of nitroheterocyclic therapeutic agents. Drug Metab Rev 19(1):33–62. https://doi.org/10.3109/03602538809049618
Kim J-w, Tchernyshyov I, Semenza GL, Dang CV (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 3(3):177–185. https://doi.org/10.1016/j.cmet.2006.02.002
Kirkpatrick DL, Powis G (2017) Clinically evaluated cancer drugs inhibiting redox signaling. Antioxid Redox Signal 26(6):262–273. https://doi.org/10.1089/ars.2016.6633
Kizaka-Kondoh S, Konse-Nagasawa H (2009) Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci 100(8):1366–1373. https://doi.org/10.1111/j.1349-7006.2009.01195.x
Koh WJ, Rasey JS, Evans ML, Grierson JR, Lewellen TK, Graham MM, Krohn KA, Griffin TW (1992) Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 22(1):199–212
Koivunen P, Hirsilä M, Günzler V, Kivirikko KI, Myllyharju J (2004) Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J Biol Chem 279(11):9899–9904. https://doi.org/10.1074/jbc.M312254200
Kolstad P (1968) Intercapillary distance, oxygen tension and local recurrence in cervix cancer. Scand J Clin Lab Invest Suppl 106:145–157
Koppenol WH, Bounds PL, Dang CV (2011) Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11(5):325–337. https://doi.org/10.1038/nrc3038
Koritzinsky M (2015) Metformin: a novel biological modifier of tumor response to radiation therapy. Int J Radiat Oncol Biol Phys 93(2):454–464. https://doi.org/10.1016/j.ijrobp.2015.06.003
Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, Dische S, Sivridis E, Harris AL (2006) Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24(5):727–735. https://doi.org/10.1200/JCO.2005.02.7474
Krol J, Loedige I, Filipowicz W (2010) The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11(9):597–610. https://doi.org/10.1038/nrg2843
Kühlbrandt W (2015) Structure and function of mitochondrial membrane protein complexes. BMC Biol 13(1):89. https://doi.org/10.1186/s12915-015-0201-x
LaGory EL, Giaccia AJ (2016) The ever expanding role of HIF in tumour and stromal biology. Nat Cell Biol 18(4):356–365. https://doi.org/10.1038/ncb3330
Lando D, Peet DJ, Gorman JJ, Whelan DA, Whitelaw ML, Bruick RK (2002) FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16(12):1466–1471. https://doi.org/10.1101/gad.991402
Larman TC, DePalma SR, Hadjipanayis AG, Cancer Genome Atlas Research N, Protopopov A, Zhang J, Gabriel SB, Chin L, Seidman CE, Kucherlapati R, Seidman JG (2012) Spectrum of somatic mitochondrial mutations in five cancers. Proc Natl Acad Sci U S A 109(35):14087–14091. https://doi.org/10.1073/pnas.1211502109
LaRocque RC, Rao SR, Lee J, Ansdell V, Yates JA, Schwartz BS, Knouse M, Cahill J, Hagmann S, Vinetz J, Connor BA, Goad JA, Oladele A, Alvarez S, Stauffer W, Walker P, Kozarsky P, Franco-Paredes C, Dismukes R, Rosen J, Hynes NA, Jacquerioz F, McLellan S, Hale D, Sofarelli T, Schoenfeld D, Marano N, Brunette G, Jentes ES, Yanni E, Sotir MJ, Ryan ET, Global TravEpiNet C (2012) Global TravEpiNet: a national consortium of clinics providing care to international travelers—analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009–2011. Clin Infect Dis 54(4):455–462. https://doi.org/10.1093/cid/cir839
Le Q-T, Chen E, Salim A, Cao H, Kong CS, Whyte R, Donington J, Cannon W, Wakelee H, Tibshirani R, Mitchell JD, Richardson D, O'Byrne KJ, Koong AC, Giaccia AJ (2006) An evaluation of tumor oxygenation and gene expression in patients with early stage non–small cell lung cancers. Clin Cancer Res 12(5):1507–1514. https://doi.org/10.1158/1078-0432.CCR-05-2049
Le Q-T, Sutphin PD, Raychaudhuri S, Yu SCT, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC, Giaccia AJ (2003) Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 9(1):59–67
Lee CT, Boss MK, Dewhirst MW (2014) Imaging tumor hypoxia to advance radiation oncology. Antioxid Redox Signal 21(2):313–337. https://doi.org/10.1089/ars.2013.5759
Lee WR, Berkey B, Marcial V, Fu KK, Cooper JS, Vikram B, Coia LR, Rotman M, Ortiz H (1998) Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma: a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 42(5):1069–1075
Liu W, Shen S-M, Zhao X-Y, Chen G-Q (2012) Targeted genes and interacting proteins of hypoxia inducible factor-1. Int J Biochem Mol Biol 3(2):165–178
Lord EM, Harwell L, Koch CJ (1993) Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 53(23):5721–5726
Lord SR, Cheng W-C, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson F, Bradley K, Wigfield S, Zois C, McGowan DR, Ah-See M-L, Thompson AM, Sharma A, Bidaut L, Pollak M, Roy PG, Karpe F, James T, English R, Adams RF, Campo L, Ayers L, Snell C, Roxanis I, Frezza C, Fenwick JD, Buffa FM, Harris AL (2018) Integrated pharmacodynamic analysis identifies two metabolic adaption pathways to metformin in breast cancer. Cell Metab 28(5):679–688.e674. https://doi.org/10.1016/j.cmet.2018.08.021
Lunt SY, Vander Heiden MG (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol 27(1):441–464. https://doi.org/10.1146/annurev-cellbio-092910-154237
Madhavan D, Peng C, Wallwiener M, Zucknick M, Nees J, Schott S, Rudolph A, Riethdorf S, Trumpp A, Pantel K, Sohn C, Chang-Claude J, Schneeweiss A, Burwinkel B (2016) Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis. Carcinogenesis 37(5):461–470. https://doi.org/10.1093/carcin/bgw008
Mäntylä MJ, Nordman EM, Ruotsalainen PJ, Kylmämaa TT (1982) Misonidazole and radiotherapy in lung cancer: a randomized double-blind trial. Int J Radiat Oncol Biol Phys 8(10):1719–1720. https://doi.org/10.1016/0360-3016(82)90292-9
Martin GV, Caldwell JH, Graham MM, Grierson JR, Kroll K, Cowan MJ, Lewellen TK, Rasey JS, Casciari JJ, Krohn KA (1992) Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med 33(12):2202–2208
Mather MW, Darrouzet E, Valkova-Valchanova M, Cooley JW, McIntosh MT, Daldal F, Vaidya AB (2005) Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. J Biol Chem 280(29):27458–27465. https://doi.org/10.1074/jbc.M502319200
McGowan DR, Skwarski M, Bradley KM, Campo L, Fenwick JD, Gleeson FV, Green M, Horne A, Maughan TS, McCole MG, Mohammed S, Muschel RJ, Ng SM, Panakis N, Prevo R, Strauss VY, Stuart R, Tacconi EMC, Vallis KA, McKenna WG, Macpherson RE, Higgins GS (2019) Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: a phase I study in patients with advanced non-small cell lung carcinoma. Eur J Cancer 113:87–95. https://doi.org/10.1016/j.ejca.2019.03.015
McNeill LA, Hewitson KS, Claridge TD, Seibel JF, Horsfall LE, Schofield CJ (2002) Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. Biochem J 367(Pt 3):571–575. https://doi.org/10.1042/BJ20021162
Melgaard B, Køhler O, Sand Hansen H, Overgaard J, Munck-Hansen J, Paulson OB (1988) Misonidazole neuropathy. A prospective study. J Neuro-Oncol 6(3):227–230
Metwally MAH, Frederiksen KD, Overgaard J (2014) Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol 53(5):654–661. https://doi.org/10.3109/0284186X.2013.864050
Michiels C, Tellier C, Feron O (2016) Cycling hypoxia: a key feature of the tumor microenvironment. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer 1866(1):76–86. https://doi.org/10.1016/j.bbcan.2016.06.004
Milosevic M, Warde P, Menard C, Chung P, Toi A, Ishkanian A, McLean M, Pintilie M, Sykes J, Gospodarowicz M, Catton C, Hill RP, Bristow R (2012) Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. Clin Cancer Res 18(7):2108–2114. https://doi.org/10.1158/1078-0432.CCR-11-2711
Mistry IN, Thomas M, Calder EDD, Conway SJ, Hammond EM (2017) Clinical advances of hypoxia-activated prodrugs in combination with radiation therapy. Int J Radiat Oncol Biol Phys 98(5):1183–1196. https://doi.org/10.1016/j.ijrobp.2017.03.024
Mookerjee SA, Gerencser AA, Nicholls DG, Brand MD (2017) Quantifying intracellular rates of glycolytic and oxidative ATP production and consumption using extracellular flux measurements. J Biol Chem 292(17):7189–7207. https://doi.org/10.1074/jbc.M116.774471
Moreno-Sánchez R, Rodríguez-Enríquez S, Marín-Hernández A, Saavedra E (2007) Energy metabolism in tumor cells. FEBS J 274(6):1393–1418. https://doi.org/10.1111/j.1742-4658.2007.05686.x
Moreno-Sánchez R, Rodríguez-Enríquez S, Saavedra E, Marín-Hernández A, Gallardo-Pérez JC (2009) The bioenergetics of cancer: is glycolysis the main ATP supplier in all tumor cells? Biofactors 35(2):209–225. https://doi.org/10.1002/biof.31
Movsas B, Chapman JD, Greenberg RE, Hanlon AL, Horwitz EM, Pinover WH, Stobbe C, Hanks GE (2000) Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 89(9):2018–2024
Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A (2002) Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 60(4):634–639
Müller M, Padberg W, Schindler E, Sticher J, Osmer C, Friemann S, Hempelmann G (1998) Renocortical tissue oxygen pressure measurements in patients undergoing living donor kidney transplantation. Anesth Analg 87(2):474–476. https://doi.org/10.1097/00000539-199808000-00045
Nehmeh SA, Lee NY, Schröder H, Squire O, Zanzonico PB, Erdi YE, Greco C, Mageras G, Pham HS, Larson SM, Ling CC, Humm JL (2008) Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 70(1):235–242. https://doi.org/10.1016/j.ijrobp.2007.08.036
Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77(1):18–24. https://doi.org/10.1016/j.radonc.2005.06.038
Nordsmark M, Eriksen JG, Gebski V, Alsner J, Horsman MR, Overgaard J (2007) Differential risk assessments from five hypoxia specific assays: the basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients. Radiother Oncol 83(3):389–397. https://doi.org/10.1016/j.radonc.2007.04.021
O'Connor JPB, Robinson SP, Waterton JC (2019) Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. Br J Radiol 92(1095):20180642. https://doi.org/10.1259/bjr.20180642
Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2(7):423–427. https://doi.org/10.1038/35017054
Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, Kuge Y, Shirato H, Tamaki N (2013) High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med 54(2):201–207. https://doi.org/10.2967/jnumed.112.109330
Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, Stanbridge EJ (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61(24):8924–8929
Orang AV, Petersen J, McKinnon RA, Michael MZ (2019) Micromanaging aerobic respiration and glycolysis in cancer cells. Mol Metab 23:98–126. https://doi.org/10.1016/j.molmet.2019.01.014
Ostheimer C, Bache M, Güttler A, Kotzsch M, Vordermark D (2014) A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer. Strahlenther Onkol 190(3):276. https://doi.org/10.1007/s00066-013-0484-1
Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, Xu Y, Wonsey D, Lee LA, Dang CV (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 275(29):21797–21800. https://doi.org/10.1074/jbc.C000023200
Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck—a systematic review and meta-analysis. Radiother Oncol 100(1):22–32. https://doi.org/10.1016/j.radonc.2011.03.004
Overgaard J, Bentzen SM, Kolstad P, Kjoerstad K, Davy M, Bertelsen K, Mäntyla M, Frankendal B, Skryten A, Löftquist I (1989a) Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 16(4):1069–1072
Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR, Danish H, Neck Cancer Study G (2005) Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 6(10):757–764. https://doi.org/10.1016/S1470-2045(05)70292-8
Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jørgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M (1989b) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16(4):1065–1068
Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, Lindeløv B, Jørgensen K (1998) A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother Oncol 46(2):135–146
Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Pt 3):607–614
Painter HJ, Morrisey JM, Mather MW, Vaidya AB (2007) Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 446(7131):88–91. https://doi.org/10.1038/nature05572
Palcic B, Brosing JW, Skarsgard LD (1982) Survival measurements at low doses: oxygen enhancement ratio. Br J Cancer 46(6):980–984
Papavasiliou C, Yiogarakis D, Davillas N, Seretakis L, Pappas J, Licourinas M, Theodorou C, Stathopoulos P, Katsoyianni C, Thanos A (1983) Treatment of bladder carcinoma with irradiation combined with misonidazole. Int J Radiat Oncol Biol Phys 9(11):1631–1633
Pastorek J, Pastoreková S, Callebaut I, Mornon JP, Zelník V, Opavský R, Zat'ovicová M, Liao S, Portetelle D, Stanbridge EJ (1994) Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9(10):2877–2888
Pernicova I, Korbonits M (2014) Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 10(3):143–156. https://doi.org/10.1038/nrendo.2013.256
Petrik D, Lavori PW, Cao H, Zhu Y, Wong P, Christofferson E, Kaplan MJ, Pinto HA, Sutphin P, Koong AC, Giaccia AJ, Le Q-T (2006) Plasma osteopontin is an independent prognostic marker for head and neck cancers. J Clin Oncol 24(33):5291–5297. https://doi.org/10.1200/JCO.2006.06.8627
Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I (2018) The hypoxic tumour microenvironment. Oncogenesis 7(1). https://doi.org/10.1038/s41389-017-0011-9
Pittman RN (2011) Regulation of tissue oxygenation. Integrated systems physiology: from molecule to function to disease. Morgan & Claypool Life Sciences, San Rafael, CA
Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH (1991) Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol 42(12):2387–2395
Qayum N, Muschel RJ, Im JH, Balathasan L, Koch CJ, Patel S, McKenna WG, Bernhard EJ (2009) Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 69(15):6347–6354. https://doi.org/10.1158/0008-5472.CAN-09-0657
Rajendran JG, Krohn KA (2005) Imaging hypoxia and angiogenesis in tumors. Radiol Clin N Am 43(1):169–187
Rajendran JG, Krohn KA (2015) F18 Fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy. Semin Nucl Med 45(2):151–162. https://doi.org/10.1053/j.semnuclmed.2014.10.006
Raleigh JA, Chou SC, Arteel GE, Horsman MR (1999) Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151(5):580–589
Rankin EB, Nam J-M, Giaccia AJ (2016) Hypoxia: signaling in the metastatic cascade. Trends Cancer 2(6):295–304. https://doi.org/10.1016/j.trecan.2016.05.006
Reznik E, Miller ML, Şenbabaoğlu Y, Riaz N, Sarungbam J, Tickoo SK, Al-Ahmadie HA, Lee W, Seshan VE, Hakimi AA, Sander C (2016) Mitochondrial DNA copy number variation across human cancers. elife 5. https://doi.org/10.7554/eLife.10769
Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ (2006) Prognostic significance of [18F]-Misonidazole positron emission tomography–detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24(13):2098–2104. https://doi.org/10.1200/JCO.2005.05.2878
Rischin D, Peters LJ, O'Sullivan B, Giralt J, Fisher R, Yuen K, Trotti A, Bernier J, Bourhis J, Ringash J, Henke M, Kenny L (2010) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 28(18):2989–2995. https://doi.org/10.1200/JCO.2009.27.4449
Scharping NE, Menk AV, Whetstone RD, Zeng X, Delgoffe GM (2017) Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia. Cancer Immunol Res 5(1):9–16. https://doi.org/10.1158/2326-6066.CIR-16-0103
Secomb TW, Hsu R, Ong ET, Gross JF, Dewhirst MW (1995) Analysis of the effects of oxygen supply and demand on hypoxic fraction in tumors. Acta Oncol 34(3):313–316
Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20(1):51–56. https://doi.org/10.1016/j.gde.2009.10.009
Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4):207–214. https://doi.org/10.1016/j.tips.2012.01.005
Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P (2005) Reduced expression of hypoxia-inducible factor-1α in perinecrotic regions of solid Tumors. Cancer Res 65(16):7259–7266. https://doi.org/10.1158/0008-5472.CAN-04-4480
Srivastava IK, Rottenberg H, Vaidya AB (1997) Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem 272(7):3961–3966. https://doi.org/10.1074/jbc.272.7.3961
Steel G (2002) Basic clinical radiobiology, 3rd edn. Oxford University Press, London
Sullivan LB, Chandel NS (2014) Mitochondrial reactive oxygen species and cancer. Cancer Metab 2. https://doi.org/10.1186/2049-3002-2-17
Świtlik WZ, Karbownik MS, Suwalski M, Kozak J, Szemraj J (2019) Serum miR-210-3p as a potential noninvasive biomarker of lung adenocarcinoma: a preliminary study. Genet Test Mol Biomarkers 23(5):353–358. https://doi.org/10.1089/gtmb.2018.0275
Szatrowski TP, Nathan CF (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 51(3):794–798
Tan AS, Baty JW, Dong L-F, Bezawork-Geleta A, Endaya B, Goodwin J, Bajzikova M, Kovarova J, Peterka M, Yan B, Pesdar EA, Sobol M, Filimonenko A, Stuart S, Vondrusova M, Kluckova K, Sachaphibulkij K, Rohlena J, Hozak P, Truksa J, Eccles D, Haupt LM, Griffiths LR, Neuzil J, Berridge MV (2015) Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab 21(1):81–94. https://doi.org/10.1016/j.cmet.2014.12.003
Thomlinson RH, Gray LH (1955) The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 9(4):539–549
Thomson D, Yang H, Baines H, Miles E, Bolton S, West C, Slevin N (2014) NIMRAD—a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin Oncol (R Coll Radiol) 26(6):344–347. https://doi.org/10.1016/j.clon.2014.03.003
Tsakiridis T, Hu C, Skinner HD, Santana-Davila R, Lu B, Erasmus JJ, Doemer A, Videtic GMM, Coster J, Yang X, Lee R, Werner-Wasik M, Schaner PE, McCormack SE, Esparaz B, McGarry R, Bazan JG, Struve T, Bradley JD (2019) Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/− metformin in locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 37(15_suppl):8502–8502. https://doi.org/10.1200/JCO.2019.37.15_suppl.8502
Varlotto J, Stevenson MA (2005) Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 63(1):25–36. https://doi.org/10.1016/j.ijrobp.2005.04.049
Vaupel P, Höckel M, Mayer A (2007) Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 9(8):1221–1236. https://doi.org/10.1089/ars.2007.1628
Vaupel P, Mayer A (2012) Availability, not respiratory capacity governs oxygen consumption of solid tumors. Int J Biochem Cell Biol 44(9):1477–1481. https://doi.org/10.1016/j.biocel.2012.05.019
Viale A, Corti D, Draetta GF (2015) Tumors and mitochondrial respiration: a neglected connection. Cancer Res 75(18):3687–3691. https://doi.org/10.1158/0008-5472.CAN-15-0491
Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC (2014) The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal 21(10):1516–1554. https://doi.org/10.1089/ars.2013.5378
Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92(12):5510–5514
Wang W, Winlove CP, Michel CC (2003) Oxygen partial pressure in outer layers of skin of human finger nail folds. J Physiol 549(Pt 3):855–863. https://doi.org/10.1113/jphysiol.2002.037994
Wang Y, Yang J, Liu H, Bi J-R, Liu Y, Chen Y-Y, Cao J-Y, Lu Y-J (2015) The association between osteopontin and survival in non-small-cell lung cancer patients: a meta-analysis of 13 cohorts. Onco Targets Ther 8:3513–3521. https://doi.org/10.2147/OTT.S94082
Weinberg SE, Chandel NS (2015) Targeting mitochondria metabolism for cancer therapy. Nat Chem Biol 11(1):9–15. https://doi.org/10.1038/nchembio.1712
Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt K-U (2003) Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 17(2):271–273. https://doi.org/10.1096/fj.02-0445fje
Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, Shah KA, Cox GJ, Corbridge RJ, Homer JJ, Musgrove B, Slevin N, Sloan P, Price P, West CML, Harris AL (2007) Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 67(7):3441–3449. https://doi.org/10.1158/0008-5472.CAN-06-3322
Wright EA, Howard-Flanders P (1957) The influence of oxygen on the radiosensitivity of mammalian tissues. Acta Radiol 48(1):26–32
Wykoff CC, Beasley NJP, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60(24):7075–7083
Yang W-H, Xu J, Mu J-B, Xie J (2017) Revision of the concept of anti-angiogenesis and its applications in tumor treatment. Chronic Dis Transl Med 3(1):33–40. https://doi.org/10.1016/j.cdtm.2017.01.002
Yu M (2011) Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. Life Sci 89(3–4):65–71. https://doi.org/10.1016/j.lfs.2011.05.010
Zannella VE, Dal Pra A, Muaddi H, McKee TD, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamiara P, Milosevic M, Wouters BG, Bristow RG, Koritzinsky M (2013) Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response. Clin Cancer Res 19(24):6741–6750. https://doi.org/10.1158/1078-0432.CCR-13-1787
Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys 12(7):1239–1242. https://doi.org/10.1016/0360-3016(86)90267-1
Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, Eguchi S, Gu J, Ma D (2018) The role of osteopontin in the progression of solid organ tumour. Cell Death Dis 9(3). https://doi.org/10.1038/s41419-018-0391-6
Zhu Y, Denhardt DT, Cao H, Sutphin PD, Koong AC, Giaccia AJ, Le Q-T (2005) Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene 24(43):6555–6563. https://doi.org/10.1038/sj.onc.1208800
Zu XL, Guppy M (2004) Cancer metabolism: facts, fantasy, and fiction. Biochem Biophys Res Commun 313(3):459–465. https://doi.org/10.1016/j.bbrc.2003.11.136
Acknowledgments
MS gratefully acknowledges the support of the Howat Foundation. JDW is grateful for support from the Royal College of Radiologists, and Oriel College, Oxford.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Skwarski, M., Bowler, E., Wilson, J.D., Higgins, G.S., Hammond, E.M. (2020). Targeting Tumor Hypoxia. In: Willers, H., Eke, I. (eds) Molecular Targeted Radiosensitizers. Cancer Drug Discovery and Development. Humana, Cham. https://doi.org/10.1007/978-3-030-49701-9_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-49701-9_11
Published:
Publisher Name: Humana, Cham
Print ISBN: 978-3-030-49700-2
Online ISBN: 978-3-030-49701-9
eBook Packages: MedicineMedicine (R0)